Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121003 | 0.89 | TSHR (0.54) | HTTTSHRMEN1KMT2ACYP1A2 | |
| SCHEMBL7126414 | 0.85 | ALDH1A1 (0.60) | TSHRMEN1KMT2ACYP3A4KDM4E | |
| SCHEMBL1097907 | 0.84 | HTT (0.75) | HTTTSHRKMT2AKDM4ECA12 | |
| SCHEMBL7117324 | 0.81 | ALDH1A1 (0.52) | HTTTSHRMEN1KMT2AKDM4E | |
| SCHEMBL11521675 | 0.81 | TSHR (0.68) | HTTTSHRMEN1KMT2ACYP1A2 | |
| SCHEMBL1962918 | 0.81 | CDC25B (0.59) | TSHRKMT2AKDM4ECDC25BHSD17B10 | |
| SCHEMBL873499 | 0.79 | TSHR (0.71) | HTTTSHRMEN1KMT2ACYP1A2 | |
| SCHEMBL29678391 | 0.79 | TSHR (0.71) | HTTTSHRMEN1KMT2ACYP1A2 | |
| SCHEMBL4502266 | 0.79 | TTR (0.53) | HTTTSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5106547 | 0.79 | TSHR (0.47) | TSHRMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9920027-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-RE46639-E1 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3101017-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2142534-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9181216-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2014-03-13 | — | — | US | disclosed |
| US-8614328-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-8153659-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2142534-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION | 2009-01-01 | — | — | US | disclosed |
| WO-2008115516-A2 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073669-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | HTT 1607/4885TSHR 4236/4885MEN1 3014/4885 |
| US-20160024048-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | HTT 1607/4885TSHR 4236/4885MEN1 3014/4885 |
| US-20090004209-A1 | 4'-O- substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | HTT 1607/4885TSHR 4236/4885MEN1 3014/4885 |
| US-20120165536-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | HTT 1607/4885TSHR 4236/4885MEN1 3014/4885 |
| US-20180155316-A1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A4, CYP3A7, CYP4B1 | HTT 1607/4885TSHR 4236/4885MEN1 3014/4885 |
| US-10385037-B2 | 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same | CYP3A4, CYP3A7, CYP4B1 | HTT 1751/4885TSHR 4235/4885MEN1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.